Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2006 1
2007 2
2008 2
2009 2
2010 5
2011 3
2013 1
2014 2
2015 1
2018 1
2020 1
2022 1
2023 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.
Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; ECASS Investigators. Hacke W, et al. N Engl J Med. 2008 Sep 25;359(13):1317-29. doi: 10.1056/NEJMoa0804656. N Engl J Med. 2008. PMID: 18815396 Free article. Clinical Trial.
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ; CLARITY Study Group. Giovannoni G, et al. N Engl J Med. 2010 Feb 4;362(5):416-26. doi: 10.1056/NEJMoa0902533. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089960 Free article. Clinical Trial.
Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials.
Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, Albers GW, Kaste M, Marler JR, Hamilton SA, Tilley BC, Davis SM, Donnan GA, Hacke W; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group; Allen K, Mau J, Meier D, del Zoppo G, De Silva DA, Butcher KS, Parsons MW, Barber PA, Levi C, Bladin C, Byrnes G. Lees KR, et al. Lancet. 2010 May 15;375(9727):1695-703. doi: 10.1016/S0140-6736(10)60491-6. Lancet. 2010. PMID: 20472172
Acupuncture in headache: a critical review.
Manias P, Tagaris G, Karageorgiou K. Manias P, et al. Among authors: karageorgiou k. Clin J Pain. 2000 Dec;16(4):334-9. doi: 10.1097/00002508-200012000-00010. Clin J Pain. 2000. PMID: 11153790 Review.
Activin-A limits Th17 pathogenicity and autoimmune neuroinflammation via CD39 and CD73 ectonucleotidases and Hif1-α-dependent pathways.
Morianos I, Trochoutsou AI, Papadopoulou G, Semitekolou M, Banos A, Konstantopoulos D, Manousopoulou A, Kapasa M, Wei P, Lomenick B, Belaidi E, Kalamatas T, Karageorgiou K, Doskas T, Sallusto F, Pan F, Garbis SD, Quintana FJ, Xanthou G. Morianos I, et al. Among authors: karageorgiou k. Proc Natl Acad Sci U S A. 2020 Jun 2;117(22):12269-12280. doi: 10.1073/pnas.1918196117. Epub 2020 May 14. Proc Natl Acad Sci U S A. 2020. PMID: 32409602 Free PMC article.
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group. Cohen JA, et al. N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089954 Free article. Clinical Trial.
Reactivity to AQP4 epitopes in relapsing-remitting multiple sclerosis.
Alexopoulos H, Kampylafka EI, Chatzi I, Travasarou M, Karageorgiou KE, Dalakas MC, Tzioufas AG. Alexopoulos H, et al. Among authors: karageorgiou ke. J Neuroimmunol. 2013 Jul 15;260(1-2):117-20. doi: 10.1016/j.jneuroim.2013.04.017. Epub 2013 May 11. J Neuroimmunol. 2013. PMID: 23673145 Free article.
Real-World Assessment of Quality of Life in Patients with Relapsing Remitting Multiple Sclerosis Treated with Teriflunomide for Two Years: Patient-Reported Outcomes from the AURELIO Study in Greece.
Dardiotis E, Perpati G, Borsos M, Nikolaidis I, Tzanetakos D, Deretzi G, Koutlas E, Kilidireas C, Mitsikostas DD, Hadjigeorgiou G, Grigoriadis N; AURELIO investigators. Dardiotis E, et al. Neurol Ther. 2022 Sep;11(3):1375-1390. doi: 10.1007/s40120-022-00384-2. Epub 2022 Jul 13. Neurol Ther. 2022. PMID: 35829919 Free PMC article.
23 results